ID 4688 -
Kwas dokozaheksaenowy, Kwas eikozapentaenowy
PL: Kwas dokozaheksaenowy, Kwas eikozapentaenowy
EN: DHA+EPA - long chain omega 3 fatty acids
Pdf: eicosapentaenoic acid
Oświadczenie (2)
- zapalne, choroby reumatyczne
- działanie przeciwzapalne
- działanie przeciwzapalne z powodu EPA i DHA
1. Charakterystyka żywności / składnika
The food constituent that is the subject of the health claims is long-chain n-3 polyunsaturated fatty acids (n-3 LCPUFAs), namely docosahexaenoic acid (DHA) in combination with eicosapentaenoic acid (EPA).
The n-3 LCPUFAs, EPA and DHA, are well recognised nutrients and are measurable in foods by established methods. They are well absorbed when consumed in the form of triglycerides. This evaluation applies to EPA and DHA from all sources with appropriate bioavailability in the specified amounts.
The Panel considers that the food constituent, DHA and EPA, which is the subject of the health claims, is sufficiently characterised.
2.10. Aktywność przeciwzapalna (ID 4688)
The claimed effect is “anti-inflammatory action due to EPA and DHA”. The Panel assumes that the target population is the general population.
From the proposed wordings, the Panel assumes that the claimed effect refers to anti-inflammatory action in the context of “inflammatory, rheumatic disease”, in which a reduction of inflammation would be a therapeutic target for the treatment of the disease.
The Panel considers that the reduction of inflammation in the context of inflammatory diseases is a therapeutic target for the treatment of a disease, and does not comply with the criteria laid down in Regulation (EC) No 1924/2006.
Warunki i możliwe ograniczenia stosowania oświadczenia